Research Progress of Glucagon-Like Peptide-1 Receptor Agonist in Endometrial Cancer
JIANG Hao-zhe
SHANG Dan-dan
WANG Shan
WAN Jin-liang
Abstract：Endometrial cancer(EC)is one of the most common malignant tumors in the female reproductive system,and its incidence is on the rise globally.Glucagon-like peptide-1 receptor agonist(GLP-1RA)as hypoglycemic drug,has gradually attracted attention for their potential role in the treatment of EC.Existing studies have preliminarily demonstrated that GLP-1RA can regulate the physiological activities of EC by activating multiple signaling pathways such as AMP-activated protein kinase(AMPK)/mammalian target of rapamycin(mTOR)and cyclic adenosine monophosphate(cAMP)/protein kinase A(PKA).This further affects apoptosis,autophagy,ferroptosis,and cell cycle arrest of EC cells,and shows the potential to overcome cisplatin chemotherapy resistance in a hyperglycemic environment,thereby inhibiting the survival,migration,and invasion abilities of EC cells.In addition,GLP-1RA can upregulate the expression of glucagon-like peptide-1 receptor(GLP-1R),and changes in the expression level of GLP-1R can be detected in both normal tissues and EC tissues.Therefore,GLP-1RA has potential application value in the treatment of EC.This review summarizes the latest research progress of GLP-1RA in the occurrence and development of EC from the perspectives of key targets,physiological mechanisms,and effects,aiming to provide reference for future research.
Keywords：Endometrial neoplasmsApoptosisAutophagyFerroptosisDrug resistanceneoplasmGlucagon-like peptide-1 receptor agonists
Publication Date：2025-10-15
Online Publishing Date：2025-11-26(First online date of this platform, not the publication date of the document)
Pages：6( 486-491 )